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WS24.5 Unresponsive patients beneﬁt from switching intravenous
antibiotic treatments for pulmonary exacerbation
D.R. VanDevanter1, M.A. O’Riordan1, J.B. Hilliard1, M.W. Konstan1. 1Case
Western Reserve University School of Medicine, Cleveland, United States
Background: CF pulmonary exacerbations (PEx) are associated with increased
morbidity and mortality and usually treated with antibiotics (ABX). We have
previously noted that IV ABX FEV1 response is essentially complete by 14 days
(Resp Res 2010, 11: 137). During PEx, we assess FEV1 weekly; poor FEV1
responses may result in a switch to a different ABX regimen. We have characterized
FEV1 responses in patients where ABX regimens have been switched.
Methods: Treatments and responses from Jan 2000 onward for PEx with dates and
FEV1 measures available from a prior stable clinic visit, ABX treatment start and
stop, and a stable follow-up visit were studied. FEV1 responses were compared for
PEx treatments with and without ABX switches.
Results: 575 PEx (69 with an ABX switch) were included. Switching ABX
increased mean treatment length and time to peak FEV1 response (P< 0.001).
Most switches occurred after 2 weeks of treatment. 75% of peak FEV1 responses
occurred after ABX switch. On average, ~2/3 of total FEV1 response occurred after
ABX switch.
Variable No ABX Switch,
N = 506 Mean
(SD)
ABX Switch,
N = 69 Mean
(SD)
P*
FEV1 Baseline, % predicted 62.2 (22.2) 63.9 (21.4) 0.42
FEV1 ABX Start, % predicted 56.7 (20.3) 55.6 (20.9) 0.70
FEV1 Peak Response, % predicted 66.8 (21.7) 65.3(21.8) 0.76
FEV1 ABX Stop, % predicted 65.3 (21.5) 63.3 (21.6) 0.54
FEV1 Follow-up, % predicted 62.4 (22.2) 61.6 (20.0) 0.98
FEV1 change Baseline to Follow-up, % predicted +0.2 (8.9) -2.3 (10.3) 0.052
Time ABX Start to Peak Response, days 13.1 (7.4) 22.8 (13.9) <0.001
Time ABX Start to Stop, days 18.1 (7.0) 31.3 (12.7) <0.001
Time ABX Start to Switch, days - 15.5 (8.6)
*non-parametric.
Conclusions: ABX switching appeared to beneﬁt unresponsive patients, but out-
comes were somewhat poorer than for patients where no switch occurred.
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Pulmonary disease due to infection with Mycobacterium abscessus complex
(MABSC) is increasingly common in patients with cystic ﬁbrosis (CF) [1]. There is
little published data on the safety and efﬁcacy of treatment regimens in CF patients.
Aim: To assess the prevalence, treatment and clinical and microbiological outcomes
of MABSC pulmonary disease in adult CF patients.
Methods: We carried out a retrospective review of all CF patients with MABSC
pulmonary disease, deﬁned by ATS criteria, attending our adult CF centre, between
January 2005 and December 2010.
Results: 17/285 (6%) patients were newly diagnosed with MABSC disease. Of
these, 15 patients (88%) were treated using a regimen consisting of an induction
period of 2−4 weeks of 3 intravenous (iv) antibiotics (amikacin, carbapenems and
tigecycline or cefoxitine), followed by a maintenance regimen involving nebulised
antibiotics (amikacin and/or meropenem) and oral antibiotics (ﬂuoroquinolone,
minocycline and a macrolide). Treated patients showed an improvement in FEV1
in the 6 months after starting therapy. Sputum conversion was noted in 9/15
(60%) patients; 5 of these patients have completed therapy and remained free
of MABSC disease. 6/15 (40%) patients stayed culture positive, most requiring
repeated admissions for iv antibiotics for exacerbations. 22 episodes of drug
reactions were recorded, including development of rash, neutropenia and liver
function abnormalities.
Discussion: Despite aggressive antibiotic therapy, successful treatment of MABSC
pulmonary disease in CF patients is difﬁcult and limited by potentially serious side
effects.
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